1977
DOI: 10.1007/bf00205434
|View full text |Cite
|
Sign up to set email alerts
|

Rejection of tumor metastases in Fischer 344 rats following the administration of killed Corynebacterium parvum

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

1977
1977
1982
1982

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 18 publications
0
5
0
Order By: Relevance
“…sarcomas Mc7 and Mc40A, animals rejecting mixed tumour cell: C. parvum inocula were immune to rechallenge but this was not apparent with the more moderately immunogenic hepatoma D23 where challenge inocula of 5x105 cells can be rejected by pre-immunized rats while animals rejecting tumour cells and C. parvum were not immune to 5 X lo3 cells. Studies in other species have shown similar patterns of reactivity, so that injection of tumour cells in admixture with C. parvum, or intralesional injection into established tumours, will suppress growth of mouse mammary carcinomas (Likhite and Halpern, 1974), fibrosarcomas (Milas et a/., 1975;Woodruff and Dunbar, 1975;Suit et al, 1976), and mastocytoma (Scott, 1976), as well as mammary carcinomas in the rat (Likhite, 1974(Likhite, , 1976) and a hamster melanoma (Paslin et al, 1974). In these situations too, animals were frequently immune to further challenge with the same tumour.…”
Section: Macrophage-depleted Ratsmentioning
confidence: 96%
“…sarcomas Mc7 and Mc40A, animals rejecting mixed tumour cell: C. parvum inocula were immune to rechallenge but this was not apparent with the more moderately immunogenic hepatoma D23 where challenge inocula of 5x105 cells can be rejected by pre-immunized rats while animals rejecting tumour cells and C. parvum were not immune to 5 X lo3 cells. Studies in other species have shown similar patterns of reactivity, so that injection of tumour cells in admixture with C. parvum, or intralesional injection into established tumours, will suppress growth of mouse mammary carcinomas (Likhite and Halpern, 1974), fibrosarcomas (Milas et a/., 1975;Woodruff and Dunbar, 1975;Suit et al, 1976), and mastocytoma (Scott, 1976), as well as mammary carcinomas in the rat (Likhite, 1974(Likhite, , 1976) and a hamster melanoma (Paslin et al, 1974). In these situations too, animals were frequently immune to further challenge with the same tumour.…”
Section: Macrophage-depleted Ratsmentioning
confidence: 96%
“…This is more rapid than the activation of AM by the injection of whole microorganisms such as Mycobacterium bovis [10,29] or Corynebacterium parvum [14,17].…”
Section: Discussionmentioning
confidence: 99%
“…The tumoricidal activity of the AM decreased by day 2 -3 after interaction with N-CWS, but a second exposure to this agent reactivated the full expression of AM-mediated tumor cytotoxicity. Because AM appear to play an important role in host defense against tumors growing in the lung [9,12,14,[20][21][22][23][24], a frequent site of metastasis [18], we wished to determine whether systemically administered squalene-treated N-CWS could activate the tumoricidal properties of rat AM, and whether multiple IV administrations of squalene-treated N-CWS could maintain levels of AM activation sufficient to eradicate established experimental pulmonary metastases of a syngeneic mammary adenocarcinoma.…”
Section: Introductionmentioning
confidence: 99%
“…If, indeed, this is the case, even under the best of conditions, specific immunotherapy would not be curative. Several experimental protocols utilizing animal models to assess the feasiblity of active specific immunotherapy as a relevant method of cancer treatment have yielded encouraging results [1,3,8,[16][17][18]29]. These studies, however, like other studies with experimental animal tumors, suffer from the restriction of utilizing transplantable tumors which may not be analagous to primary tumors.…”
Section: Introductionmentioning
confidence: 99%
“…These studies, however, like other studies with experimental animal tumors, suffer from the restriction of utilizing transplantable tumors which may not be analagous to primary tumors. For example, it has been postulated that whereas primary or early-passage tumors may exhibit marked immunologic heterogeneity, this heterogeneity is lost as a consequence of repeated in vivo passage [6,18]. The significance of such immunologic variability, or the lack thereof, must be taken into account in the design and evaluation of immunotherapy models using transplantable tumors.…”
Section: Introductionmentioning
confidence: 99%